GlassScriptPhysician profile
Robert P Landry
NPI 1841297124
$12,677.81
in general payments reported to CMS, 2019-2025
44 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $730 · 2021: $2,131 · 2022: $5,258 · 2023: $1,241 · 2024: $1,102 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.38 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,856.86 | 2021-2024 | Ellipsys Vascular Access System, Chameleon |
| Astrazeneca Pharmaceuticals LP | $1,307.05 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $594.38 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $532.00 | 2022-2025 | |
| Amgen INC. | $458.97 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $432.80 | 2019-2025 | Velphoro, Velphoro |
| Bard Peripheral Vascular, INC. | $392.30 | 2019-2020 | |
| Vifor Pharma, INC. | $379.60 | 2019-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $259.63 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $241.69 | 2019-2024 | Auryxia |
| Novartis Pharmaceuticals Corporation | $235.22 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $183.16 | 2022-2025 | Lupkynis |
| Daiichi Sankyo INC. | $166.35 | 2019-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $156.42 | 2023-2025 | Terlivaz, Acthar |
| Opko Pharmaceuticals, LLC | $151.18 | 2019-2025 | Rayaldee |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $112.59 | 2022-2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.10 | 2024-2025 | Jardiance |
| Genzyme Corporation | $103.52 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $91.56 | 2019-2025 | Gore Viabahn Endoprosthesis |
| Nxstage Medical, INC. | $76.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $71.97 | 2020-2024 | Ultomiris |
| Horizon Therapeutics Plc | $67.33 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $61.08 | 2023-2025 | Jardiance |
| Abiomed | $60.22 | 2020 | |
| Biotronik INC. | $60.04 | 2022 | |
| Cormedix INC. | $58.39 | 2024 | Defencath |
| Ultragenyx Pharmaceutical INC. | $44.69 | 2019-2023 | |
| Novo Nordisk INC | $43.04 | 2025 | Rybelsus, Ozempic, Wegovy |
| Covidien LP | $41.24 | 2020 | |
| Glaxosmithkline, LLC. | $36.42 | 2020-2023 | Jesduvroq |
| Travere Therapeutics, INC. | $34.90 | 2023 | |
| Mallinckrodt Enterprises LLC | $34.82 | 2019 | |
| Mozarc Medical US LLC | $30.14 | 2023 | Argyle, Chameleon |
| Hikma Pharmaceuticals USA | $22.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.86 | 2025 | Tryvio |
| Ardelyx, INC. | $18.92 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $18.63 | 2025 | Empaveli |
| Abbott Laboratories | $18.39 | 2023 | Diamondback Peripheral |
| Medtronic Vascular, INC. | $18.01 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.66 | 2024 | Jynarque |
| Shire North American Group INC | $17.00 | 2019 | |
| Allergan, INC. | $15.76 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2019 | |
| Dentsply Sirona INC | $14.00 | 2024 | Suresmile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.